Follow us on Twitter
twitter icon@FreshPatents

Dextran patents

Bulk PDF Downloads
      

This page is updated frequently with new Dextran-related patent applications.




 Medium supplements for improved process performance patent thumbnailMedium supplements for improved process performance
The present invention pertains to a cell culture medium comprising dextran sulfate or a mixture of dextran sulfate and ferric citrate, and methods of using thereof. The present invention further pertains to a method of producing a protein of interest in a large scale cell culture, comprising supplementing the cell culture with dextran sulfate or a mixture of dextran sulfate and ferric citrate..
Biogen Ma Inc.


 Biodegradable microbeads with improved anticancer drug adsorptivity, containing albumin and dextran sulfate, and preparation method therefor patent thumbnailBiodegradable microbeads with improved anticancer drug adsorptivity, containing albumin and dextran sulfate, and preparation method therefor
The present invention relates to: biodegradable microbeads with improved anticancer drug adsorptivity, containing albumin and dextran sulfate; a preparation method therefor; and a method for treating cancer using the same. The microbeads of the present invention is prepared from a biocompatible and biodegradable polymer so as to be safe to the human body, and can effectively inhibit the growth of a tumor by effectively blocking a blood vessel which supplies nutrition to a liver tumor and continuously releasing an anticancer drug adsorbed on surfaces of the beads.
Utah-inha Dds & Advanced Therapeutics Research Center


 Construction of new variants of dextransucrase dsr-s by genetic engineering patent thumbnailConstruction of new variants of dextransucrase dsr-s by genetic engineering
The present invention relates to a recombinant process for the production of truncated or mutated dextransucrases while conserving the enzymatic activity or their specificity in the synthesis of the α-1,6 bonds. The present invention relates to nucleic acid sequences of truncated or mutated dextransucrases, vectors containing the nucleic acid sequences and host cells transformed by sequences encoding truncated or mutated dextransucrases.
Institut National Des Sciences Appliquees De Toulouse


 Glycan profiling utilizing capillary electrophoresis patent thumbnailGlycan profiling utilizing capillary electrophoresis
A method for glycan profiling by capillary electrophoresis (ce), and a ce system for glycan analysis (n-glycan). The ce system uses integrated dual optical fibers for both radiation excitation and emission detection.
Bioptic, Inc.


 Cryoprotecting agent, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation patent thumbnailCryoprotecting agent, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation
The present invention relates to a cryoprotecting agent comprising a cryprotectant being one or more of: dextrin, dextran, isomaltooligosaccharide and derivatives thereof, cryoprotecting and cryopreserved compositions, uses thereof, and methods of cryopreservation.. .
Pharmacosmos A/s


 Freeze-dried excipient and preparation method thereof patent thumbnailFreeze-dried excipient and preparation method thereof
A freeze-dried excipient and a preparation method thereof. The freeze-dried excipient only comprises an active ingredient and a binder, and does not comprise a support agent.

 Gamma stabilized dextran solutions and methods of use patent thumbnailGamma stabilized dextran solutions and methods of use
Provided herein are gamma stable dextran solutions and kits that increase the efficiency of blood separation by allowing the dextran solution to be sterilized by exposure to gamma radiation and maintain sufficient molecular weight to act as a red blood cell aggregant. Further provided are methods of use..
General Electric Company


 Encapsulated benefit agents patent thumbnailEncapsulated benefit agents
The invention provides improved deposition and reduced leakage benefits from a particle comprising: (a) a core comprising a benefit agent; (b) a shell, wherein the shell comprises a crosslinked, hydrophobically modified polyvinyl alcohol, which comprises a crosslinking agent comprising i) a first dextran aldehyde having a molecular weight of from 2,000 to 50,000 da; and ii) a second dextran aldehyde having a molecular weight of from greater than 50,000 to 2,000,000 da.. .

 Water-based ink for ink-jet recording, water-based ink set for ink-jet recording, and treatment agent patent thumbnailWater-based ink for ink-jet recording, water-based ink set for ink-jet recording, and treatment agent
A water-based ink for ink-jet recording includes a self-dispersible pigment which is modified with phosphate group, at least one of dextran and a derivative thereof, and water.. .
Brother Kogyo Kabushiki Kaisha


 Absorbable compositions and methods for their use in hemostasis patent thumbnailAbsorbable compositions and methods for their use in hemostasis
The present invention is direct to a body-absorbable, mechanically hemostatic composition comprising a solid poloxamer having an average molecular weight of about 7,000 g/mol to about 15,000 g/mol, a high molecular weight dextran, optionally a fatty acid salt, and water, and a method for mechanically controlling the bleeding of bone comprising applying an effective amount of the composition to the affected area.. .
Pioneer Surgical Technology, Inc.


Injectable solution at ph 7 comprising at least one basal insulin whose pi is between 5.8 and 8.5


A composition in the form of an injectable aqueous solution, the ph of which is between 6.0 and 8.0, includes at least a basal insulin, the isoelectric point pi of which is between 5.8 and 8.5; and a dextran substituted by radicals carrying carboxylate charges and hydrophobic radicals. Single-dose formulations at a ph of between 7 and 7.8 includes a basal insulin whose isoelectric point is between 5.8 and 8.5 and a prandial insulin..
Adocia


Dextran-peptide hybrid for efficient gene delivery


One or more embodiments of the present invention provide a novel composition for gene delivery are directed to a group of polysaccharide polymers, having one or more nucleic acid delivery side chains comprising cationic peptides. In some embodiments, these cationic peptides condense and physically bond to one or more nucleic acids to form a polysaccharide-nucleic acid complex that permits delivery to and transfection of the nucleic acid(s) into cells.
The University Of Akron


Colonic drug delivery formulation


A delayed release coating comprising a mixture of a first material selected from starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan, and a second material which has a ph threshold at about ph 5 or above, is used to target release of a drug from a core to the intestine, particularly the colon.. .
University College London


Traditional chinese medicine composition for pigment repair


The invention provides a composition for use in traditional chinese medicine to repair the pigment, wherein said composition comprises the following parts by weight of the composition ratio of raw material: 5-10 parts water, rhodiola extract 2-6 copies, snow lotus root extract 3-5 parts, 1-5 parts egeria motherwort extract, vitamin-c2-3 copies, copies of oat amino acids 2-5, 2-3 parts of dextran, 1-2 parts of emu oil, astragalus extract 2-3 parts, 4-5 parts of ginseng root extract, angelica extract 2-3 parts. This composition helps dilute pigment and redness, thickening of the skin to make the skin more resistant to ease fragile, net flashed white luster..
Shang Chen Mei Bang (beijing) Biotechnology Co., Ltd.


Traditional chinese medicine composition for dispelling wringles and black eye and its preparation method


The invention provides a composition and method for preparing medicine for eye bags and dark circles fade, wherein said composition comprises the following parts by weight ratio of raw material composition: 10-15 parts water, ganoderma lucidum extract 2-3 copies, black ganoderma extract 3-4, 5-6 parts wheat germ oil, sucrose laurate 2-3 parts, 3-5 parts chamomile extract, 3-5 parts of milk protein, yeast ferment filtrate 3-5 copies, dextran 2-3 copies, copies tremella 2-4, 2-3 parts angelica root extract, astragalus extract 2-3 parts. The above described method for preparing a composition according to the present invention, without any side effects, can be soft smooth skin around the eyes, remove free radicals, enhance the resilience of the skin, thereby improving eye skin color, to get rid of dark circles effect..
Shang Chen Mei Bang (beijing) Biotechnology Co., Ltd.


Evaluation and preservation solution


An evaluation and preservation solution for human and animal organs, tissues and parts thereof is described, wherein it comprises serum albumin at a concentration of 55-105 g/l, a scavenger and coating compound, preferably dextran compounds and derivatives thereof having essentially the same structure at a concentration of 1-55 g/l weight, and a physiological serum concentration of salts and nutrients in a physiologically acceptable medium.. .
Xvivo Perfusion Ab


Compositions comprising short-acting benzodiazepines


A composition is provided with a benzodiazepine and at least one hygroscopic excipient, in particular lactose and/or dextran.. .
Paion Uk Limited


Multi-layered anti-adhesion device


Compositions and methods are provided for preparing an adhesion barrier in the form of a foldable or flexible biodegradable polymer matrix that effectively reduces, prevents or treats adhesions in a patient in need thereof. In one embodiment, the matrix comprises a first porous layer comprising collagen and a second porous layer comprising collagen and dextran, wherein the dextran is loaded in the second layer in an amount of from about 5% to about 90% by weight based on a total weight of the matrix.

Waterborne topical compositions for the delivery of azelaic acid for treatment of skin conditions such as acne vulgaris, rosacea, seborrheic dermatitis


A waterborne topical composition is designed specifically to address the treatment of acne vulgaris, rosacea, seborrheic dermatitis and other skin conditions. One composition contains effective amounts of essential components azelaic acid, niacinamide, and glycerin to create a rapidly penetrating and non-irritating compound.
Epikinetics Pharma, Llc


Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Electrospun dextran fibers and devices formed therefrom


The invention generally relates to dextran fibers which are preferably electrospun and devices formed from such fibers. In particular, such devices may include substances of interest (such as therapeutic substances) associated with the electrospun fibers.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.


Method for peptide histochemical diagnosis


The present invention provides a method of peptide histochemical diagnosis to detect the peptide binding protein in the cancer tissue. This peptide binding specifically to tumor cells is linked to the dextran coated iron oxide nanoparticle.
National Taiwan University


Dextran-based polymer tissue adhesive for medical use


A tissue adhesive formed by reacting an aminodextran containing primary amine groups with an oxidized dextran containing aldehyde groups is described. The dextran-based polymer tissue adhesive is particularly useful in medical applications where low swell and slow degradation are needed, for example sealing the dura, ophthalmic procedures, tissue repair, antiadhesive applications, drug delivery, and as a plug to seal a fistula or the punctum..
Actamax Surgical Materials, Llc


Method of producing current collector for electrochemical element, producing electrode for electrochemical element, current collector for electrochemical element, electrochemical element, and coating liquid for fabricating current collector for electrochemical element


An object of the present invention is to provide a method of producing a current collector for an electrochemical element that enable rapid charging and discharging with low internal resistance. The method of producing a current collector for an electrochemical element in the present invention has a step for coating a coating liquid onto a metal foil, the coating liquid containing at least one substance selected from the group consisting of methyl cellulose, ethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl ethyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl starch, hydroxypropyl starch, dextrin, pullulan, dextran, guar gum and hydroxypropyl guar gum; an organic acid having valence of two or more or a derivative thereof, carbon particles and an organic solvent, followed by removing the organic solvent and forming a coating layer on the metal foil..
Dainichiseika Color & Chemicals Mfg. Co., Ltd.


Prebiotic composition or pharmaceutical composition synthesized from catalytic domains producing highly alpha-1,2 branched dextran


The invention relates to an isolated polypeptide with an glycosyl transferase enzymatic activity for producing dextrans with .alpha.(1.fwdarw.2) sidechains, comprising at least one region for bonding to glucan and a catalytically active region situated beyond the region bonding to glucan. The invention further relates to polynucleotides coding for said enzymes and vectors containing the same..
Institut National Des Sciences Appliquees (insa)


Serum-free mammalian cell culture medium, and uses thereof


The present invention provides a cell culture medium formulation that supports the in vitro cultivation, particularly in suspension, of mammalian cells, particularly epithelial cells and fibroblast cells, and methods for cultivating mammalian cells in suspension in vitro using these media. The media comprise a basal medium and a polyanionic or polyanionic compound, preferably a polysulfonated or polysulfated compound, and more preferably dextran sulfate.
Life Technologies Corporation


Assay label


This invention relates to an assay label comprising an amorphous carbon particle, a functionalised dextran polymer attached to the surface of the carbon particle and a first member of a complementary binding pair covalently bonded to the functionalised dextran polymer. The invention also provides a device incorporating the assay label, which further comprises a radiation source adapted to generate a series of pulses of electromagnetic radiation at a wavelength such that the absorption of the radiation by the label generates energy by non-radiative decay; a sample chamber containing a transducer having a pyroelectric or piezoelectric element and electrodes which is capable of transducing energy generated by non-radiative decay into an electrical signal; and a detector which is capable of detecting the electrical signal generated by the transducer..
Vivacta Limited


Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders


A method of diagnosing a cd206 expressing cell-related disorder by administering a pharmaceutical composition to a subject, the composition including a carrier molecule having a detectable moiety attached thereto. The carrier molecule has a dextran backbone, and at least one receptor substrate conjugated, directly or indirectly, to the dextran backbone, wherein the receptor substrate is chosen so as to specifically bind to cd206.
Ohio State Innovation Foundation


Compositions and methods for making alpha-(1,2)-branched alpha-(1,6) oligodextrans


Compositions for improving the health of a subject comprise alpha-(1,2)-branched alpha-(1,6) oligodextrans, preferably with an average molecular weight between about 10 kda and 70 kda, between about 10% and 50% alpha-(1,2)-osidic side chains, and having at least partial indigestibility in the subject. Methods for improving the health of a subject comprise administering the composition to a subject in an amount effective to improve gut health, or to prevent or treat a gastrointestinal disorder, a cholesterol-related disorder, diabetes, or obesity.
Tate & Lyle Ingredients France Sas


Stabalized glycosaminoglycan preparations and related methods


Compositions comprising a glycosaminoglycan (e.g., a hyaluronan, hyaluronic acid, hyaluronate, sodium hyaluronate, dermatan sulfate, karatan sulfate, chondroitin 6-sulfate, heparin, etc.) in combination with at least one component selected from; i) polyglycols (e.g., polyethylene glycol), ii) long chain hydroxy polyanionic polysaccharides (e.g., dextran, sodium alginate, alginic acid, propylene glycol alginate, carboxymethyl cellulose and carboxyethyl cellulose, hydroxyl ethyl starch, hydroxyl propyl methyl cellulose, hydroxy propyl ethyl cellulose, hydroxy propyl cellulose, methyl cellulose, polylysine, polyhistidine, polyhydroxy proline, poly ornithine, polyvinyl pyrolidone, polyvinyl alcohol, chitosan, etc.) and iii) long chain nitrogen containing polymers (e.g., polylysine, polyvinylpyrrolidone, and polyvinyl alcohol). The invention also includes methods for using such compositions (e.g., as substance delivery materials, tissue fillers or bulking agents, as moistening or hydrating agents, etc.).

Dextran-based tissuelette containing platelet-rich plasma lysate for cartilage repair


The invention relates to a dextran-based tissuelette comprising platelet-rich plasma lysate (prpl), which can be used for tissue repair. In particular, the tissuelette of the present invention can be adapted to display properties similar to natural cartilage, while having increased chondrocyte-attraction.

Iron oxide nanocapsule, manufacturing the same, and mri contrast agent using the same


Provided is an iron oxide nanocapsule which has extremely excellent water dispersibility, which is very stable in the body and which has very excellent mri contrast ability, a method of manufacturing the same, and an mri contrast agent using the same. The method of manufacturing the iron oxide nanocapsule includes the steps of: thermally decomposing an iron complex to prepare hydrophobic ligand-bonded iron oxide nanoparticles; and encapsulating the hydrophobic ligand-bonded iron oxide nanoparticles by a carboxymethyldextrandodecylamine conjugate encapsulation material or a dextran-linoleic acid conjugate encapsulation material to form an iron oxide nanocapsule..

Sample collection kit


A sample collection kit includes a sample collector, a polycarbonate container, and a preservative solution. The sample collector includes an absorbent pad with a collecting element that receives a sample of oral fluid.

Antidandruff agent sulfated polysaccharides


The invention relates to the cosmetic use of a sulfated polysaccharide chosen from: dextran sulfate and sulfated polysaccharides derived from the red alga porphyridium sp, as active agent for preventing and/or treating dandruff of the scalp.. .

Ophthalmological aqueous composition


The present invention provides an aqueous ophthalmic composition containing (a) a terpenoid, (b) zinc chloride, and (c) at least one member selected from the group consisting of cellulose-based polymeric compounds, vinyl-based polymeric compounds, polyethylene glycols and dextran. According to the present invention, an aqueous ophthalmic composition is provided in which adsorption of the terpenoid to a container can be inhibited, thereby making it possible to inhibit the reduction in the terpenoid content for a long period of time, the aqueous ophthalmic composition having some excellent actions such as an inhibitory action for histamine release, and an inhibitory action for discharges from the eyes..

Polyol and polyether iron oxide complexes as pharmacological and/or mri contrast agents


Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran.

In-situ cross-linkable polymeric compositions and methods thereof


A biocompatible polymeric composition for cross-linking in-situ in a wound is disclosed comprising 1) one or more polyanionic polymers such as alginates or hyaluronates, able to be cross-linked the surface of the wound and 2) one or more polycationic polymers such as chitosan or deae-dextran, that assists in the solidification process as well as speeds up hemostasis without the need for applying pressure. The biocompatible polymeric composition may further comprise a cross-linking agent such as aqueous calcium chloride.

Hydrogel and producing same


A hydrogel is provided which is obtained by reacting an azide group and a cyclooctyne group in the absence of a catalyst, especially in the absence of a copper catalyst. The hydrogel has: (a) a first polymer moiety composed of hyaluronic acid, carboxymethyl dextran or the like; (b) a second polymer moiety composed of hyaluronic acid, carboxymethyl dextran or the like, said second polymer moiety being of a kind that is same as or different from the kind of the moiety (a) and is composed of a molecule different from the moiety (a); and (c) a triazole ring group or a derivative group thereof..

Medical fluid comprising globulin and its use for preservation of harvested organs


A medical fluid for a harvested organ, tissue or parts thereof, for evaluation and/or preservation. The fluid comprise oncotic agents, comprising albumin, a dextran compound and at least one globulin.

Plasmonic stable fluorescence superparamagnetic iron oxide nanoparticles and a synthesizing the same


The various embodiments herein provide for the engineered multimodal super paramagnetic iron oxide nanoparticles (spions) with a fluorescent dye. The spions comprise fluorescent polymer dye arranged in a gap between a spion core and a gold shell.

Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Benefit agent delivery particles comprising dextran


The invention provides a composition comprising a benefit agent delivery particle comprising dextran as a delivery aid. The benefit agent delivery particle may further comprise a non-polysaccharide polymer, preferably an aminoplast polymer.

Methods and compositions for inhibiting cellular proliferation and surgical adhesion


The present invention provides compositions and methods to inhibit fibrosis and scarring associated with surgery. The present invention relates to the discovery that a synthetic anionic polymer consisting of dextran-sulfate (anionic carbohydrate) conjugated to tirofiban (an anti-platelet agent which prevents platelet activation and aggregation) can effectively inhibit adhesions that form during surgery.

Polyol and polyether iron oxide complexes as pharmacological and/or mri contrast agents


Iron oxide complexes, pharmacological compositions and unit dosage thereof, and methods for their administration, of the type employing an iron oxide complex with a polyol, are disclosed. The pharmacological compositions employ a polysaccharide iron oxide complex, wherein the polysaccharide is a modified polyol such as a carboxyalkylated reduced dextran.

Inkjet inks


The present disclosure provides inkjet inks and associated methods and systems. In one example, an inkjet ink can comprise an ink vehicle and a colorant, wherein the ink vehicle includes an organic co-solvent, water, and from 0.0001 wt % to 0.1 wt % dextran based on the inkjet ink as a whole..

Pharmaceutical compositions of dextran polymer derivatives


Pharmaceutical compositions are provided comprising an active agent and a dextran polymer derivative. The compositions include from 0.01 to 99 wt % of an active agent and from 1 to 99.99 wt % of a dextran polymer derivative.

Clearance buffer


The invention concerns a composition comprising tcep, biotin and dextran suitable for liquefying a viscous biological sample. The composition according to the invention can be used in diagnostic methods, preferably for use in diagnosis of an infection with a micro-organism, more preferably for use in diagnosis of hcap..

Method for manufacture of dextran, dextran solution obtained, and uses


Microbiological method of production of a dextran solution, according to which a culture medium containing sucrose is inoculated with a preculture of a bacterial strain that is able to produce dextran, then the dextran solution obtained at the end of fermentation is recovered directly, without a subsequent concentration step, characterized in that:—before inoculation, the culture medium contains at least 10 wt. % of sucrose,—after inoculation, sucrose is added again in conditions such that the total amount of sucrose in the medium, including that present before inoculation, is at least 16 wt.

Compositions and methods for inhibiting adhesion formation


Compositions and methods are provided for preparing an adhesion barrier that effectively reduce, prevent or treat adhesions in a patient in need thereof. In one embodiment, a matrix is provided comprising a biodegradable polymer and dextran loaded in the matrix in an amount of from about 5% to about 90% by weight based on a total weight of the matrix.

Devices and methods for inhibiting adhesion formation


Methods and compositions are provided for reducing, treating or preventing adhesions in a patient in need of such treatment. In one embodiment, an implantable device is provided for reducing or preventing adhesion formation at a post-operative tissue site in a patient, the implantable device including a biodegradable porous matrix comprising dextran, wherein the implantable device is capable of releasing the dextran over at least 2 days..

Cb-183,314 compositions and related methods


The present disclosure provides novel solid cb-183,315 formulations which have improved chemical stability. The chemical stability of the solid cb-183,315 is dependent on the process by which the composition is made.

Compositions and methods for inhibiting bone growth


Compositions and methods are provided for a matrix that inhibits bone growth in a patient in need thereof. In one embodiment, a method of inhibiting bone growth is provided, the method comprising: implanting a matrix at a target tissue site, the matrix comprising a biodegradable polymer and dextran loaded in the matrix in an amount of from about 5% to about 95% by weight based on a total weight of the matrix..

In vivo visualization of lymphatic tissue


Aspects of the invention include methods for visualizing lymphatic tissue in an ocular region, e.g., the cornea, of a living subject, such as a mouse or human. In certain embodiments, the methods include contacting the region with a fluorescently-labeled lymphatic tissue-specific dye, e.g., fitc or rhodamine labeled dextran, and detecting the labeled dye to visualize lymphatic tissue in the region, where the visualization may vary, from an image obtained at a single time to a video over a period of time.

Seed coating hydrogels


A bio-degradeable seed coating composition for enhanced seed protection and propagation comprises a gelatin-based hydrogel formulation consisting of a naturally derived, hydrophilic protein in combination with a sulfated or non-sulfated polysaccharide. The protein is animal porcine or bovine derived while the polysaccharide is preferably a cellulose derivative such as sodium cellulose sulfate, dextran sulfate, sulfated chitosan, sulfated starch and mixtures thereof.

Use of dextran sulfate


A method of inhibiting instant blood-mediated inflammatory reaction (ibmir) in a patient, comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof. A method of inhibiting morphological disruption of a transplanted cell transplant in a patient comprises administering a therapeutically effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, to a patient.

Use of dextran sulfate


A graft composition intended for transplantation into a patient comprises an injection solution comprising an isolated cell transplant and dextran sulfate, or a pharmaceutically acceptable salt thereof.. .

Cartilage repair mixture containing allograft chondrocytes


The invention is directed toward a sterile cartilage defect implant material comprising milled lyophilized allograft cartilage pieces ranging from 0.01 mm to 1.0 mm in size in a bioabsorbable carrier taken from a group consisting of sodium hyaluronate, hyaluronic acid and its derivatives, gelatin, collagen, chitosan, alginate, buffered pbs, dextran or mixed polymers with allograft chondrocytes added in an amount ranging from 2.5×105 to 2.5×107.. .

Process for delivering encapsulated neutral bioimaging molecules, complex, and process thereof


The present disclosure relates to delivering neutral bioimaging molecules encapsulated within icosahedral dna capsules in vivo and in vitro. The present disclosure also discloses the entrapment of neutral bioimaging molecules like fitc dextran within the cavity of a dna polyhedron without any molecular recognition or chemical conjugation between host (dna icosahedron) and cargo (like fitc dextran).

Trace elements


The invention discloses a trace element solution, which comprises at least one metal selected from the group comprising selenium, copper, zinc, manganese and chromium; and at least one component selected from the group comprising a vitamin, a vaccine, a growth stimulant, a dewormer, iron dextran, an antibiotic and a synchronisation preparation. The synchronisation preparation is a combination of injectable hormonal preparations, inplantable hormonal preparations, intravaginal hormonal preparation and other slow release hormonal preparation.

Method of stably treating incontinence using a bulking agent


The invention provides a method for treating fecal incontinence in a subject comprising administering in an appropriate subject a therapeutically effective amount of a biocompatible bulking agent to the wall of the anal canal. The biocompatible bulking agent comprises dextranomer and a pseudoplastic carrier, such as, hyaluronic acid, and is stable and effective in treating fecal incontinence for over 24 months, and up to at least 36 months or more following an initial administration..

Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion


An ophthalmic solution is provided. The ophthalmic solution is hypertonic.

Order a batch download of a huge number of patent PDFs. Bulk PDF Downloads This is a premium service.

Hypertonic dextran solution and methods of treating and preventing recurrent corneal erosion


An ophthalmic solution is provided. The ophthalmic solution is hypertonic.

Stabilized enzyme compositions


A medical device includes a base material having an immobilized enzyme and dextran sulfate. The dextran sulfate has a molecular weight that is less than 40 kilo dalton (kda).

Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran


The subject invention relates to the compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran with technetium-99m and for stabilizing the dtpa-dextran cold kit. The composition contains stannous chloride ions to reduce 99mtc-pertechnetate, ascorbic acid to reduce stannic ions to stannous ions to maintain a reducing environment, α,α-trehalose to add bulk and to stabilize the lyophilized composition without interfering with the radiochemical yield, and glycine to transchelate technetium-99m under highly acidic conditions to facilitate radiolabeling dtpa-dextran with high radiochemical purity.

Method of increasing the stability of a bayer process liquor


Methods, and related products and compositions, of increasing the stability of a bayer process liquor are described. A method of increasing the stability of a bayer process liquor includes contacting the bayer process liquor with a ppm quantity of a low molecular weight dextran.

Nanoparticle delivery system and components thereof


The present disclosure relates generally to a nanoparticle delivery system. The nanoparticles are formed from amphiphilic block copolymers comprising polylactide and dextran.

Method of stably treating incontinence using a bulking agent


The invention provides a method for treating fecal incontinence in a subject comprising administering in an appropriate subject a therapeutically effective amount of a biocompatible bulking agent to the wall of the anal canal. The biocompatible bulking agent comprises dextranomer and a pseudoplastic carrier, such as, hyaluronic acid, and is stable and effective in treating fecal incontinence for over 24 months, and up to at least 36 months or more following an initial administration..



Dextran topics:
  • Recombinant
  • Recombinant Protein
  • Ophthalmic
  • Ascorbic Acid
  • Polysaccharides
  • Ethylene Glycol
  • Hydroquinone
  • Cultured Cells
  • Culture Media
  • Epithelial
  • Epithelial Cell
  • Eukaryotic
  • Fibroblast
  • Cell Culture Media
  • Magnetic Field


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Dextran for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Dextran with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.3355

    3101

    1 - 1 - 72